drugset / Trial / NCT05216224
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
Timeline
- Start
- 2021-12-29
- Primary completion
- 2022-12-23
- Completion
- 2023-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zunsemetinib | Small molecule | 50 mg | Oral |